Delivery Order SPE2DR25D2002-SPE2DR26FBTA4
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,097.78 for Ondansetron ODT 4 mg tablets (30-count supply) on November 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating it was competitively awarded. Performance is scheduled for completion by December 1, 2025, and work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,151.89 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count packages), with an ultimate completion date of December 23, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a $17,662.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count package) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,544.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count package) on July 29, 2025, with completion targeted for July 30, 2025. This competitive award—utilizing firm fixed pricing with no set-aside designation—represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,371.93 delivery order for Ondansetron ODT 4 mg tablets (30-count) on November 28, 2025, with an ultimate completion date of December 1, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,589.33 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) with a completion deadline of June 27, 2025. This competitive award, issued under a firm fixed-price contract structure with no set-aside designation, represents a continuation of AmerisourceBergen's ongoing pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count units) under a firm fixed-price contract valued at $26,561.64. The award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count) under a firm fixed-price contract valued at $8,420.18. The award, issued on December 19, 2025, with an ultimate completion date of December 22, 2025, represents a competitively awarded, non-set-aside transaction. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,618.73 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) on December 4, 2025, with completion scheduled for December 5, 2025. The award is a firm fixed price delivery order with no set-aside designation, indicating competitive selection. Performance will be executed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DR25D2002Indefinite Delivery Contract
- SPE2DR25D2002-SPE2DR26FBTA4Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,888.29 for Ondansetron ODT 8 mg tablets (30-count packages) on January 5, 2026, with completion scheduled for January 6, 2026. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems through its comprehensive medical supply chain contracts with the DLA. The parent IDC vehicle enables the company to supply a broad range of pharmaceutical products, generic medications, brand-name drugs, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs globally. This specific delivery order for Ondansetron, a common anti-nausea medication used in clinical settings, represents routine pharmaceutical procurement under the broader pharmaceutical prime vendor framework that the DLA maintains to ensure consistent supply of essential medications to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 1/4/26 |